MedTrace Logo

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

NCT04480814 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-12-30

No results posted yet for this study

Summary

Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.

Liquid biopsy is a non-invasive approach based on the extraction of information through peripheral blood analysis. It makes it possible to characterize the development of a solid tumor in real time, through detailed molecular analysis of circulating genetic material in peripheral blood.

Conditions

Interventions

DIAGNOSTIC_TEST

PIK3CA kit

Prospective investigation of clinical samples for evaluation of IVD clinical performance

Sponsors & Collaborators

  • University of Athens

    collaborator OTHER

  • Pharmassist Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-11
Primary Completion
2022-02-08
Completion
2022-02-08

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480814 on ClinicalTrials.gov